Regen BioPharma, Inc. (RGBP)
Oxford Ledge is still expanding full research coverage of RGBP. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Regen Biopharma develops regenerative and immunotherapy treatments through clinical trials, with one program cleared to initiate Phase I testing.
Source: 10-K (2025-09-30) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-14
- 8-K 3.02 2026-03-04
- 10-Q Quarterly financial report (unaudited) 2026-02-13
- 8-K 3.02 2026-02-02
- 8-K Other material event 2026-01-21
Source: SEC EDGAR.
Annual results
5 years of annual figures for RGBP, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $236,561 | -$1.3M | -$0.05 |
| 2024 | $236,560 | -$668,255 | -$0.16 |
| 2023 | $236,560 | $1.2M | $0.29 |
| 2022 | $125,517 | $2.4M | $0.71 |
| 2021 | $61,194 | -$6.8M | — |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
- Open RGBP in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.